Health & Fitness
Health and Fitness
Health and Fitness
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009 Eurand N.V.: Eurand Announces International Agreements for Once-Daily Extended Release Muscle Relaxant
MILAN, ITALY--(Marketwire - March 17, 2009) - Eurand N.V. (
The respective pharmaceutical partners will be commercializing the product, subject to regulatory review and approval, in the following countries:
-- TURKEY - Nobel Ilac A.S. -- ISRAEL - PharmaSwiss SA -- SOUTH AFRICA - Adcock Ingram
"These agreements represent important milestones in expanding Eurand's cyclobenzaprine ER franchise into new territories," said John Fraher, Eurand's Chief Commercial Officer.
As announced in August 2008, Eurand signed a license and supply agreement with Daewoong Pharmaceuticals Co. Ltd, a leading South Korean pharmaceutical company. Under terms of the agreement, Daewoong will commercialize cyclobenzaprine ER in South Korea, subject to regulatory approval.
Developed using Eurand's innovative Diffucaps® technology, cyclobenzaprine ER is a centrally acting muscle relaxant indicated as an adjunct to rest for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Cephalon markets the product in the U.S. under the brand name Amrix®. Cyclobenzaprine ER is available for licensing in certain other countries.
About Nobel Ilac
Nobel Ilac A.S. is one of the leading pharmaceutical companies in Turkey with successful marketing and sales strategies in the domestic and international market, supported by a vertical integration of developing and manufacturing API (active pharmaceutical ingredients) and pharmaceuticals. The product portfolio of Nobel comprises self-developed/manufactured pharmaceuticals, in-licensed pharmaceuticals and OTC products. Nobel is also one of the main exporters of pharmaceuticals in Turkey. With 2200 employees throughout its subsidiaries in 15 countries, Nobel is outstanding with its global structure through which it offers its high quality services and products as it does in Turkey. For more information, visit [ www.nobel.com.tr/en/ ].
About PharmaSwiss SA
Established in 2000 and based in Zug, Switzerland, PharmaSwiss offers full third-party representation of specified drugs or portfolios from research-based pharmaceutical and biotech companies, including drug registration, promotion, sales, compliance and pharmacovigilance. It represents several blue chip clients such as Amgen, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Ipsen, Astellas Pharma, Eli Lilly and Ferring. PharmaSwiss currently operates in Serbia, Croatia, Slovenia, Poland, Baltic countries, Czech Republic, Hungary, Romania, Bulgaria, Slovakia, Albania, Greece, Turkey and Israel. During the course of 2008, PharmaSwiss has launched operations in Hungary, Romania and Turkey and during 2009 in Poland. Development plans for the following years include also entering Russia and CIS. The company has nearly 600 employees and achieved turnover of EUR 132 million in 2008. For more information, visit [ www.pharmaswiss.com ].
About Adcock Ingram
Adcock Ingram is a leading South African pharmaceutical company with a history that spans 117 years of adding value to the lives of millions of South Africans. The company has an extensive range of prescription, generic and OTC products and also provides life saving hospital equipment, diagnostic products and services. The extensive range of over-the-counter and prescription products of original research and generic medicines was recently enhanced by the addition of a range of generic antiretroviral medicines. The company's in-house research and development facilities are approved by the South African Medicines Control Council and accredited by the World Health Organisation. The company is extending its footprint in Sub-Saharan African and international markets. For more information, visit [ www.adcock.co.za ].
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at [ www.eurand.com ].
Forward-Looking Statement
This release, and oral statements made with respect to information contained in this release, may constitute forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to the future and status of the Company's partnering plans for its products and anticipated product launches. The words "potentially," "anticipates," "could," "calls for" and similar expressions can also help identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Investors are advised to refer to the Company's Risk Factors set forth in its Annual Report on Form-20-F as filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.
